Dose-Finding and Dose-Schedule Dose-Escalation

1. Wong, C.H., Siah, K.W. and Lo, A.W., 2019. Estimation of clinical trial success rates and related parameters. *Biostatistics*, *20*(2), pp.273-286.
2. Conaway, M.R. and Petroni, G.R., 2019. The Impact of Early-Phase Trial Design in the Drug Development ProcessThe Role of Early-Phase Design. *Clinical Cancer Research*, *25*(2), pp.819-827.
3. Wheeler, G.M., Mander, A.P., Bedding, A., Brock, K., Cornelius, V., Grieve, A.P., Jaki, T., Love, S.B., Odondi, L.O., Weir, C.J. and Yap, C., 2019. How to design a dose-finding study using the continual reassessment method. *BMC medical research methodology*, *19*(1), pp.1-15.
4. O'Quigley, J., Pepe, M. and Fisher, L., 1990. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. *Biometrics*, pp.33-48.
5. Whitehead, J. and Williamson, D., 1998. Bayesian decision procedures based on logistic regression models for dose-finding studies. *Journal of Biopharmaceutical Statistics*, *8*(3), pp.445-467.
6. Neuenschwander, B., Branson, M. and Gsponer, T., 2008. Critical aspects of the Bayesian approach to phase I cancer trials. *Statistics in medicine*, *27*(13), pp.2420-2439.
7. Ji, Y., Liu, P., Li, Y. and Nebiyou Bekele, B., 2010. A modified toxicity probability interval method for dose-finding trials. *Clinical trials*, *7*(6), pp.653-663.
8. Abbas, R., Rossoni, C., Jaki, T., Paoletti, X. and Mozgunov, P., 2020. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation. *Clinical Trials*, *17*(5), pp.522-534.
9. Riviere, M.K., Yuan, Y., Dubois, F. and Zohar, S., 2014. A Bayesian dose-finding design for drug combination clinical trials based on the logistic model. *Pharmaceutical statistics*, *13*(4), pp.247-257.
10. Mozgunov, P., Knight, R., Barnett, H. and Jaki, T., 2021. Using an interaction parameter in model-based phase I trials for combination treatments? A simulation study. *International journal of environmental research and public health*, *18*(1), p.345.
11. Neuenschwander, B., Matano, A., Tang, Z., Roychoudhury, S., Wandel, S. and Bailey, S.A., 2015. Bayesian industry approach to phase I combination trials in oncology. *Statistical methods in drug combination studies*, *2015*, pp.95-135.
12. Wages, N.A., Conaway, M.R. and O'Quigley, J., 2011. Continual reassessment method for partial ordering. *Biometrics*, *67*(4), pp.1555-1563.
13. Wages, N.A., Conaway, M.R. and O'Quigley, J., 2011. Dose-finding design for multi-drug combinations. *Clinical Trials*, *8*(4), pp.380-389.
14. Wages, N.A. and Conaway, M.R., 2013. Specifications of a continual reassessment method design for phase I trials of combined drugs. *Pharmaceutical statistics*, *12*(4), pp.217-224.
15. Mozgunov, P. and Jaki, T., 2019. An information theoretic phase I–II design for molecularly targeted agents that does not require an assumption of monotonicity. *Journal of the Royal Statistical Society: Series C (Applied Statistics)*, *68*(2), pp.347-367.
16. Yan, F., Zhang, L., Zhou, Y., Pan, H., Liu, S. and Yuan, Y., 2020. BOIN: an R package for designing single-agent and drug-combination dose-finding trials using Bayesian optimal interval designs. *Journal of Statistical Software*, *94*, pp.1-32.
17. Mander, A.P. and Sweeting, M.J., 2015. A product of independent beta probabilities dose escalation design for dual-agent phase I trials. *Statistics in medicine*, *34*(8), pp.1261-1276.
18. Mozgunov, P., Gasparini, M. and Jaki, T., 2020. A surface-free design for phase I dual-agent combination trials. *Statistical methods in medical research*, *29*(10), pp.3093-3109.
19. Bailey, S., Neuenschwander, B., Laird, G. and Branson, M., 2009. A Bayesian case study in oncology phase I combination dose-finding using logistic regression with covariates. *Journal of biopharmaceutical statistics*, *19*(3), pp.469-484.
20. Mozgunov, P., Jaki, T. and Paoletti, X., 2019. Randomized dose-escalation designs for drug combination cancer trials with immunotherapy. *Journal of Biopharmaceutical Statistics*, *29*(2), pp.359-377.
21. Mozgunov, P., Cro, S., Lingford-Hughes, A., Paterson, L.M. and Jaki, T., 2022. A dose-finding design for dual-agent trials with patient-specific doses for one agent with application to an opiate detoxification trial. *Pharmaceutical statistics*, *21*(2), pp.476-495.
22. Ewings, S., Saunders, G., Jaki, T. and Mozgunov, P., 2022. Practical recommendations for implementing a Bayesian adaptive phase I design during a pandemic. *BMC medical research methodology*, *22*(1), pp.1-15.
23. Mozgunov, P., Jaki, T., et.al, 2022. Practical Implementation of the Partial Ordering Continual Reassessment Method in a Phase I Combination-Schedule Dose-Finding Trial. Statistics in Medicine. Epub
24. Yap, C., Billingham, L.J., Cheung, Y.K., Craddock, C. and O'Quigley, J., 2017. Dose Transition Pathways: The Missing Link Between Complex Dose-Finding Designs and Simple Decision-MakingDose Transition Pathways in Model-Based Dose-Finding Designs. *Clinical Cancer Research*, *23*(24), pp.7440-7447.